Immunologic Efficacy Of E39 & E39 ' Vaccination In A Phase I/Iia Trial In Ovarian And Endometrial Cancer Patients.

75Background: The treatment options for cancer are ever-evolving u0026 now include vaccines targeting tumor-specific immunogenic peptides to induce tumor cytolysis. Folate binding protein (FBP) is a tumor-associated antigen (TAA) highly expressed in most endometrial u0026 ovarian cancers (Ca), shielded from the normal immune system. The most promising FBP peptides are E39 u0026 an attenuated form, E39u0027 (aka J65). In our most recent phase I/IIa trial we evaluated an E39+GM-CSF inoculation series at 3 doses (VG) vs controls (CG) as well as booster vaccination with E39 or E39u0027 after the initial inoculation series. Here we present the immunologic data from this phase I/IIa trial. Methods: Patients (pts) with ovarian or endometrial Ca who were disease-free after standard of care therapy but at risk for recurrence were enrolled. HLA-A2+ pts were vaccinated in a 3+3 dose escalation of 100mcg, 500mcg, u0026 1000mcg. The remaining pts received 1000mcg inoculations. Vaccine was given every 3-4 weeks for a total of 6 inoculums. Pts...